Markets:

Overview

News

Currencies

International

Treasuries

Can-Fite Biopharma Ltd American Depositary Shares (NY:CANF)

3.499 -0.041 (-1.15%)

Streaming Delayed Price Updated: 3:12 PM EDT, May 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >

Can-Fite Revenue FY22 Revenue Declines 4.7%, Here Is What You Need To Know ↗

March 30, 2023

Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE:CANF) revenues for the year ended December 31, 2022 were $810,000, a decrease of $43,000, or 4.7%, compared to revenues of $853,000 during the twelve months...

Via Benzinga

Can-Fite Reports 2022 Financial Results & Provides Clinical Update

March 30, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson

March 16, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting

March 13, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

February 14, 2023

During Tuesday, 40 stocks hit new 52-week lows.

Via Benzinga

Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo

February 14, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

February 10, 2023

During Friday, 48 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

January 25, 2023

On Wednesday, 22 companies hit new 52-week lows.

Via Benzinga

Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed

January 24, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement

January 11, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow

January 10, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Stocks That Hit 52-Week Lows On Wednesday ↗

January 04, 2023

On Wednesday, 35 companies reached new 52-week lows.

Via Benzinga

Can-Fite Announces ADS Ratio Change

December 30, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite's Namodenoson Increases Survival For Most Severe Patients With Advanced Liver Cancer ↗

December 28, 2022

Via Benzinga

Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer

December 28, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Multiple Shots On Goal: Can-Fite’s Late-Stage Clinical Pipeline Hits Positive Results

December 27, 2022

By Ernest Dela Aglanu, Benzinga

Via News Direct

Multiple Shots On Goal: Can-Fite’s Late-Stage Clinical Pipeline Hits Positive Results

December 27, 2022

Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer.

Via TheNewswire.com

Multiple Shots On Goal: Can-Fite's Late-Stage Clinical Pipeline Hits Positive Results ↗

December 13, 2022

Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer.

Via Benzinga

Can-Fite’s Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets’ Osteoarthritis

December 08, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update

November 25, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Meet This BioPharma Company With Several Exciting Drugs In Advanced Clinical Trials ↗

November 09, 2022

Sign up for this week’s All Access giveaway here! Pnina Fishman, Ph.D., CEO of Can-Fite BioPharma (NYSE: CANF), was a guest on Benzinga’s All Access on Nov 4, 2022.

Via Benzinga

Can-Fite: Positive New Data from it’s Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston

November 02, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers

October 31, 2022

The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.

Via TheNewswire.com

This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers ↗

October 27, 2022

The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.

Via Benzinga

Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®

October 25, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference

October 13, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite BioPharma Ltd. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

September 23, 2022

Via ACCESSWIRE

Can-Fite Reports Second Quarter 2022 Financial Results & Provides Clinical Update

August 25, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology

September 12, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

August 23, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.